An open-label single-dose and multiple-dose safety, tolerability, and pharmacokinetics study of sofosbuvir/GS-5816 in healthy Chinese subjects
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
Most Recent Events
- 25 Oct 2024 New source identified and integrated China Drug Trials (CTR20160602).
- 05 Mar 2020 New trial record
- 27 Feb 2020 Results published in the Clinical Therapeutics